Zhengye Biotechnology Holding Limited Announces Financial Results for the First Six Months of Fiscal Year 2026

Revenue and profit fell, but gross margin improved and losses narrowed for Zhengye Biotechnology.

What the company is saying

Zhengye Biotechnology Holding Limited, led by co-CEOs Songlin Song and Aiden Han, reports a focus on profitability through cost management and operational efficiency despite a decline in net revenue and gross profit. The company highlights an improved gross profit margin of 32.9%, up from 31.1%, attributing this to better margins in the 'other vaccines' segment. Operating expenses dropped 22.2% year-over-year to RMB37.6 million, and the net loss narrowed by 13.3% to RMB22.2 million. Management explains that lower revenues stemmed from cost-cutting by key customers and weak market demand, particularly in swine and poultry vaccines. The company emphasizes ongoing product development, targeting expansion into household animal vaccines and new international markets, including Africa, Central Asia, and West Asia. The tone is measured, with management expressing confidence in long-term growth through financial discipline, resource allocation, and talent retention.

What the data suggests

Net revenue for the six months ended June 30, 2026, was US$7.5 million, down 18.3% from the previous year's US$9.2 million equivalent. Gross profit declined to US$2.5 million, but gross profit margin improved to 32.9% from 31.1%, mainly due to the 'other vaccines' segment moving from a negative margin to breakeven. Swine vaccine revenue was US$5.6 million, poultry vaccines US$1.0 million, and other vaccines US$0.9 million, all lower year-over-year due to reduced sales volumes and weak demand. Operating expenses fell to US$5.5 million, with sales and marketing, G&A, and R&D costs all reduced, partly because of lower payroll, travel, and the absence of IPO-related one-time fees. Net loss narrowed to US$3.3 million, and loss per share improved to US$0.06. Cash fell to US$4.7 million from US$7.4 million at year-end, with negative operating and investing cash flows only partially offset by US$0.7 million in financing inflows. The company remains loss-making, with shrinking revenue and cash, but has improved cost control and margin discipline.

Analysis

The announcement is a factual interim financial report with no exaggerated or promotional tone. All key claims about revenue, profit, loss, margins, and cash flow are directly supported by disclosed numerical data. While management includes several forward-looking statements about long-term growth, market expansion, and strategic initiatives, these are presented as aspirations rather than imminent or guaranteed outcomes. The financial results themselves show declining revenue and continued net losses, with only a modest improvement in gross margin. There is no evidence of narrative inflation or overstatement: the language is measured, and the operational and financial realities are clearly disclosed. No large capital outlay or immediate earnings impact is discussed, and the forward-looking statements are generic rather than hyped.

Risk flags

• ●Sustained revenue decline is a core risk: net revenue dropped 18.3% year-over-year to US$7.5 million, reflecting weak demand and customer cost-cutting. This trend, if persistent, threatens future profitability and cash generation.
• ●The company remains unprofitable, posting a net loss of US$3.3 million for the period. Although the loss narrowed, continued losses may pressure liquidity and limit investment in growth initiatives.
• ●Cash reserves decreased to US$4.7 million as of June 30, 2026, down from US$7.4 million at year-end, with negative operating and investing cash flows. This raises the risk of future capital needs or dilution if losses persist.
• ●Gross margins in poultry vaccines remain negative at -2.9%, and 'other vaccines' only barely broke even at 0.4%. This exposes the company to further margin pressure if sales mix shifts or costs rise.
• ●International expansion and new product development are framed as long-term goals, but no concrete milestones, regulatory approvals, or commercial agreements are disclosed. Execution risk is high given the lack of near-term visibility.

Bottom line

Zhengye Biotechnology's interim results show declining revenue and ongoing net losses, but the company has improved its gross margin and reduced operating expenses. Management attributes the revenue drop to weak industry demand and customer cost-cutting, while highlighting cost discipline and operational efficiency as positives. Cash burn continues, with reserves falling to US$4.7 million, and the company remains reliant on future financing or a turnaround in sales to sustain operations. The narrative of international expansion and new product development is aspirational, with no immediate catalysts or detailed execution roadmap. Investors should focus on whether the company can stabilize revenue, return to profitability, and deliver on its strategic ambitions before considering a more positive outlook. The most important takeaway is that while cost control is improving, the core challenge remains reversing the top-line decline and achieving sustainable profitability.

Announcement summary

(NASDAQ:ZYBT) Zhengye Biotechnology Holding Limited announced its unaudited financial results for the six months ended June 30, 2026. Net revenue was RMB50.9 million (US$7.5 million) for the period, down from RMB62.3 million in the same period last year. Gross profit was RMB16.7 million (US$2.5 million), compared to RMB19.4 million last year. Gross profit margin improved to 32.9%, up 1.8 percentage points from 31.1% in the prior year, mainly due to improved margins in the other vaccines segment. Net loss was RMB22.2 million (US$3.3 million), a decrease from RMB25.6 million last year. Basic and diluted loss per share was RMB0.40 (US$0.06), compared to RMB0.46 in the prior year. Revenue from swine vaccines was RMB38.2 million (US$5.6 million), poultry vaccines RMB6.5 million (US$1.0 million), and other vaccines RMB6.2 million (US$0.9 million). Cost of revenue was RMB34.2 million (US$5.0 million), down from RMB42.9 million last year. Total operating expenses were RMB37.6 million (US$5.5 million), down from RMB48.3 million. Sales and marketing expenses were RMB18.6 million (US$2.7 million), general and administrative expenses RMB13.7 million (US$2.0 million), and research and development expenses RMB4.8 million (US$0.7 million). As of June 30, 2026, the company had cash of RMB31.9 million (US$4.7 million), compared to RMB50.3 million as of December 31, 2025. Net cash used in operating activities was RMB16.8 million (US$2.5 million), net cash used in investing activities was RMB5.7 million (US$0.8 million), and net cash provided by financing activities was RMB4.6 million (US$0.7 million). The company’s products are exported to Vietnam, Pakistan, and Egypt. The company operates three veterinary vaccine production floors with 13 production lines, a quality examination center, and an animal facility for vaccine development. The exchange rate used for currency translation was RMB6.7851 to US$1.00 as of June 30, 2026. The company’s gross profit margin for swine vaccines was 44.3%, for poultry vaccines negative 2.9%, and for other vaccines 0.4% for the six months ended June 30, 2026. The company’s total assets as of June 30, 2026, were RMB411.99 million (US$60.72 million), and total liabilities were RMB128.57 million (US$18.95 million). Shareholders’ equity was RMB229.79 million (US$33.87 million), and noncontrolling interests were RMB53.62 million (US$7.90 million). The company’s operating loss was RMB20.8 million (US$3.1 million) for the six months ended June 30, 2026. The company’s products are available in 29 provincial regions across China and are exported to Vietnam, Pakistan, and Egypt.

Disagree with this article?